A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infectionRichard Elion, Javier Szwarcberg, Jean‐Michel Molina et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2013Cited by 41